

# Walid F Gellad

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5742205/publications.pdf>

Version: 2024-02-01

109  
papers

2,243  
citations

279487

23  
h-index

253896

43  
g-index

110  
all docs

110  
docs citations

110  
times ranked

3383  
citing authors

#	ARTICLE	IF	CITATIONS
1	Medication Adherence to Multidrug Regimens. <i>Clinics in Geriatric Medicine</i> , 2012, 28, 287-300.	1.0	159
2	Evaluation of Machine-Learning Algorithms for Predicting Opioid Overdose Risk Among Medicare Beneficiaries With Opioid Prescriptions. <i>JAMA Network Open</i> , 2019, 2, e190968.	2.8	134
3	Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses. <i>Clinical Therapeutics</i> , 2017, 39, 1456-1478.e36.	1.1	120
4	Antibiotic Therapy for Adults Hospitalized With Community-Acquired Pneumonia. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 593.	3.8	115
5	Tight Glycemic Control and Use of Hypoglycemic Medications in Older Veterans With Type 2 Diabetes and Comorbid Dementia. <i>Diabetes Care</i> , 2015, 38, 588-595.	4.3	104
6	The Role of Opioid Analgesics in Geriatric Pain Management. <i>Clinics in Geriatric Medicine</i> , 2016, 32, 725-735.	1.0	95
7	Association between trajectories of buprenorphine treatment and emergency department and inpatient utilization. <i>Addiction</i> , 2016, 111, 892-902.	1.7	88
8	Accelerated Approval and Expensive Drugs – A Challenging Combination. <i>New England Journal of Medicine</i> , 2017, 376, 2001-2004.	13.9	68
9	Using Machine Learning to Examine Medication Adherence Thresholds and Risk of Hospitalization. <i>Medical Care</i> , 2015, 53, 720-728.	1.1	67
10	Trajectories of Diabetes Medication Adherence and Hospitalization Risk: A Retrospective Cohort Study in a Large State Medicaid Program. <i>Journal of General Internal Medicine</i> , 2016, 31, 1052-1060.	1.3	67
11	Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program. <i>JAMA Network Open</i> , 2020, 3, e2020969.	2.8	66
12	The Veterans Choice Act and Dual Health System Use. <i>Journal of General Internal Medicine</i> , 2016, 31, 153-154.	1.3	61
13	The myths of medication adherence. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1437-1441.	0.9	58
14	Medication-Assisted Treatment and Opioid Use Before and After Overdose in Pennsylvania Medicaid. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 750.	3.8	54
15	Trajectories of Oral Anticoagulation Adherence Among Medicare Beneficiaries Newly Diagnosed With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2019, 8, e011427.	1.6	48
16	Dual Use of Department of Veterans Affairs and Medicare Benefits and Use of Test Strips in Veterans With Type 2 Diabetes Mellitus. <i>JAMA Internal Medicine</i> , 2015, 175, 26.	2.6	45
17	Overprescribing of Opioids to Adults by Dentists in the U.S., 2011–2015. <i>American Journal of Preventive Medicine</i> , 2020, 58, 473-486.	1.6	43
18	Race/Ethnicity and Sex-Related Differences in Direct Oral Anticoagulant Initiation in Newly Diagnosed Atrial Fibrillation: A Retrospective Study of Medicare Data. <i>Journal of the National Medical Association</i> , 2020, 112, 103-108.	0.6	34

#	ARTICLE	IF	CITATIONS
19	Variation in Drug Prices at Pharmacies: Are Prices Higher in Poorer Areas?. Health Services Research, 2009, 44, 606-617.	1.0	31
20	Evaluation of Flibanserin. JAMA - Journal of the American Medical Association, 2015, 314, 869.	3.8	31
21	Trends in List Prices, Net Prices, and Discounts for Originator Biologics Facing Biosimilar Competition. JAMA Network Open, 2019, 2, e1917379.	2.8	31
22	Using machine learning to predict risk of incident opioid use disorder among fee-for-service Medicare beneficiaries: A prognostic study. PLoS ONE, 2020, 15, e0235981.	1.1	27
23	Overlapping buprenorphine, opioid, and benzodiazepine prescriptions among veterans dually enrolled in Department of Veterans Affairs and Medicare Part D. Substance Abuse, 2017, 38, 22-25.	1.1	26
24	Characteristics of Opioid Prescriptions to Veterans With Cirrhosis. Clinical Gastroenterology and Hepatology, 2019, 17, 1165-1174.e3.	2.4	25
25	Trends in Medicaid Prices, Market Share, and Spending on Long-Acting Insulins, 2006-2018. JAMA - Journal of the American Medical Association, 2019, 321, 1627.	3.8	25
26	Dual Receipt of Prescription Opioids From the Department of Veterans Affairs and Medicare Part D and Prescription Opioid Overdose Death Among Veterans. Annals of Internal Medicine, 2019, 170, 433.	2.0	25
27	Older Patient and Caregiver Perspectives on Medication Value and Deprescribing: A Qualitative Study. Journal of the American Geriatrics Society, 2020, 68, 746-753.	1.3	25
28	Pharmacy Use in the First Year of the Veterans Choice Program. Medical Care, 2017, 55, S26-S32.	1.1	23
29	Medication adherence as a learning process: insights from cognitive psychology. Health Psychology Review, 2017, 11, 17-32.	4.4	21
30	Initial Experience Prescribing Commercial Tafamidis, the Most Expensive Cardiac Medication in History. JAMA Cardiology, 2020, 5, 1066.	3.0	20
31	Developing and validating a machine-learning algorithm to predict opioid overdose in Medicaid beneficiaries in two US states: a prognostic modelling study. The Lancet Digital Health, 2022, 4, e455-e465.	5.9	20
32	Adherence to Anticoagulation and Risk of Stroke Among Medicare Beneficiaries Newly Diagnosed with Atrial Fibrillation. American Journal of Cardiovascular Drugs, 2020, 20, 199-207.	1.0	19
33	Capitalizing on Prescribing Pattern Variation to Compare Medications for Type 2 Diabetes. Value in Health, 2014, 17, 854-862.	0.1	17
34	Off-label Drug Use and Adverse Drug Events. JAMA Internal Medicine, 2016, 176, 63.	2.6	17
35	Prescribing of Clozapine and Antipsychotic Polypharmacy for Schizophrenia in a Large Medicaid Program. Psychiatric Services, 2017, 68, 579-586.	1.1	17
36	Characteristics Associated With Opioid and Antibiotic Prescribing by Dentists. American Journal of Preventive Medicine, 2021, 60, 648-657.	1.6	17

#	ARTICLE	IF	CITATIONS
37	VA and Medicare Utilization Among Dually Enrolled Veterans with Type 2 Diabetes: A Latent Class Analysis. <i>Journal of General Internal Medicine</i> , 2016, 31, 524-531.	1.3	16
38	Antihypertensive Deprescribing in Older Adult Veterans at End of Life Admitted to Veteran Affairs Nursing Homes. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 132-140.e5.	1.2	16
39	Low-Value Prostate Cancer Screening Among Older Men Within the Veterans Health Administration. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 1922-1927.	1.3	15
40	Medicaid Coverage "Cliff" Increases Expenses And Decreases Care For Near-Poor Medicare Beneficiaries. <i>Health Affairs</i> , 2021, 40, 552-561.	2.5	15
41	Lock-In Programs and the Opioid Epidemic: A Call for Evidence. <i>American Journal of Public Health</i> , 2016, 106, 1918-1919.	1.5	12
42	Impact of Star Rating Medication Adherence Measures on Adherence for Targeted and Nontargeted Medications. <i>Value in Health</i> , 2019, 22, 1266-1274.	0.1	12
43	Evaluation of Low-Value Diagnostic Testing for 4 Common Conditions in the Veterans Health Administration. <i>JAMA Network Open</i> , 2020, 3, e2016445.	2.8	12
44	Marked Increase in Sales of Erectile Dysfunction Medication During COVID-19. <i>Journal of General Internal Medicine</i> , 2021, 36, 2912-2914.	1.3	12
45	Comparison of Dental Benzodiazepine Prescriptions From the U.S., England, and Australia From 2013 to 2018. <i>American Journal of Preventive Medicine</i> , 2021, 61, 73-79.	1.6	12
46	Outpatient Prescribing of Antibiotics and Opioids by Veterans Health Administration Providers, 2015-2017. <i>American Journal of Preventive Medicine</i> , 2021, 61, e235-e244.	1.6	12
47	Variation in Formulary Management Practices Within the Department of Veterans Affairs Health Care System. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2016, 22, 114-120.	0.5	11
48	Prescription Opioid Quality Measures Applied Among Pennsylvania Medicaid Enrollees. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2018, 24, 875-885.	0.5	11
49	Rural access to MAT in Pennsylvania (RAMP): a hybrid implementation study protocol for medication assisted treatment adoption among rural primary care providers. <i>Addiction Science &amp; Clinical Practice</i> , 2019, 14, 25.	1.2	11
50	Adalimumab and the Challenges for Biosimilars. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 2171.	3.8	11
51	Opioid Prescribing Safety Measures in Medicaid Enrollees With and Without Cancer. <i>American Journal of Preventive Medicine</i> , 2019, 57, 540-544.	1.6	11
52	Origins of the Crisis in Insulin Affordability and Practical Advice for Clinicians on Using Human Insulin. <i>Current Diabetes Reports</i> , 2020, 20, 2.	1.7	11
53	New chronic disease medication prescribing by nurse practitioners, physician assistants, and primary care physicians: a cohort study. <i>BMC Health Services Research</i> , 2016, 16, 312.	0.9	10
54	Buprenorphine Dispensing in Pennsylvania During the COVID-19 Pandemic, January to October 2020. <i>Journal of General Internal Medicine</i> , 2021, 36, 3915-3917.	1.3	10

#	ARTICLE	IF	CITATIONS
55	Development of a Metric to Detect and Decrease Low-Value Prescribing in Older Adults. JAMA Network Open, 2022, 5, e2148599.	2.8	10
56	Myocarditis after vaccination against covid-19. BMJ, The, 2021, 375, n3090.	3.0	10
57	Use and Cost of Low-Value Health Services Delivered or Paid for by the Veterans Health Administration. JAMA Internal Medicine, 2022, 182, 832.	2.6	10
58	Patterns of opioid prescriptions received prior to unintentional prescription opioid overdose death among Veterans. Research in Social and Administrative Pharmacy, 2019, 15, 1007-1013.	1.5	9
59	Socially optimal pandemic drug dosing. The Lancet Global Health, 2021, 9, e1049-e1050.	2.9	9
60	Trends in Opioid Prescribing by General Dentists and Dental Specialists in the U.S., 2012–2019. American Journal of Preventive Medicine, 2022, 63, 3-12.	1.6	8
61	Implications of recent clinical trials on pay-for-performance. American Journal of Health-System Pharmacy, 2009, 66, 864-867.	0.5	7
62	Prescriber perspectives on <sc>low-value</sc> prescribing: A qualitative study. Journal of the American Geriatrics Society, 2021, 69, 1500-1507.	1.3	7
63	Incidence and Predictors of Primary Nonadherence to Sodium Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide 1 Agonists in a Large Integrated Healthcare System. Journal of General Internal Medicine, 2022, 37, 3562-3569.	1.3	7
64	Implications of New Insurance Coverage for Access to Care, Cost-Sharing, and Reimbursement. JAMA - Journal of the American Medical Association, 2014, 311, 241.	3.8	6
65	A New Safe Harbor – Turning Drug Rebates into Discounts in Medicare Part D. New England Journal of Medicine, 2019, 380, 1688-1690.	13.9	6
66	Dosing profiles of concurrent opioid and benzodiazepine use associated with overdose risk among US Medicare beneficiaries: group-based multi-trajectory models. Addiction, 2022, 117, 1982-1997.	1.7	6
67	Long-term disease and economic outcomes of prior authorization criteria for Hepatitis C treatment in Pennsylvania Medicaid. Healthcare, 2017, 5, 105-111.	0.6	5
68	Potentially Inappropriate Medication Combination with Opioids among Older Dental Patients: A Retrospective Review of Insurance Claims Data. Pharmacotherapy, 2020, 40, 992-1001.	1.2	5
69	Use of a medication-based risk adjustment index to predict mortality among veterans dually-enrolled in VA and medicare. Healthcare, 2019, 7, .	0.6	4
70	Characteristics of dual drug benefit use among veterans with dementia enrolled in the Veterans Health Administration and Medicare Part D. Research in Social and Administrative Pharmacy, 2019, 15, 701-709.	1.5	4
71	Comparison of Oral Anticoagulant Use and Stroke Risk Among Older Adults Newly-Diagnosed Atrial Fibrillation Living in Urban-Versus-Rural Areas. American Journal of Cardiology, 2020, 130, 64-69.	0.7	4
72	Trends in List and Net Prices of Self-administered Systemic Psoriasis Therapies Manufactured by US-Based Pharmaceutical Companies. JAMA Dermatology, 2020, 156, 1136.	2.0	4

#	ARTICLE	IF	CITATIONS
73	High-Dose Opioid Use Among Veterans with Unexplained Gastrointestinal Symptoms Versus Structural Gastrointestinal Diagnoses. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3938-3950.	1.1	4
74	Predicting Mortality Risk After a Hospital or Emergency Department Visit for Nonfatal Opioid Overdose. <i>Journal of General Internal Medicine</i> , 2021, 36, 908-915.	1.3	4
75	Opioid Prescribing by Dentists in the Veterans Health Administration. <i>American Journal of Preventive Medicine</i> , 2022, 63, 371-383.	1.6	4
76	Association of formulary restrictions and initiation of an SGLT2i or GLP1-RA among Medicare beneficiaries with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2022, 187, 109855.	1.1	4
77	Maximizing the Post-Approval Safety of Flibanserin: A Role for Regulators, Clinicians, and Patients. <i>Drug Safety</i> , 2016, 39, 375-380.	1.4	3
78	Commentary on Daubresse et al. (2017): An epidemic of outdated data. <i>Addiction</i> , 2017, 112, 1054-1055.	1.7	3
79	Limitations Concerning the Association of Physician Sex and Patient Outcomes. <i>JAMA Internal Medicine</i> , 2017, 177, 1058.	2.6	3
80	Lowering the <i>P</i> Value Threshold. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 935.	3.8	3
81	Modernizing Medicaid Managed Care. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1559.	3.8	2
82	Prescription of Brand-Name Medications When Generic Alternatives Are Available—Patently Unfair. <i>JAMA Internal Medicine</i> , 2016, 176, 1323.	2.6	2
83	Decreasing Health Care Spending Through Market Competition—A Case for the Rapid Adoption of Adalimumab Biosimilars. <i>JAMA Internal Medicine</i> , 2020, 180, 903.	2.6	2
84	Occupational Patterns of Opioid-Related Overdose Deaths Among Arizona Medicaid Enrollees, 2008—2017. <i>Journal of General Internal Medicine</i> , 2020, 35, 2210-2213.	1.3	2
85	Trends in list prices, net prices, and discounts of self-administered injectable tumor necrosis factor inhibitors. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2021, 27, 112-117.	0.5	2
86	Access to Affordable Insulin and Epinephrine Autoinjectors Through Federally Qualified Health Centers. <i>JAMA Health Forum</i> , 2021, 2, e210313.	1.0	2
87	A decade of increases in Medicare Part B pharmaceutical spending: what are the drivers?. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2021, 27, 565-573.	0.5	2
88	Trends in the Use of Conventional and New Pharmaceuticals for Hemophilia Treatments Among Medicaid Enrollees, 2005-2020. <i>JAMA Network Open</i> , 2021, 4, e2112044.	2.8	2
89	Characteristics of Opioid Prescriptions to Veterans With Chronic Gastrointestinal Symptoms and Disorders Dually Enrolled in the Department of Veterans Affairs and Medicare Part D. <i>Military Medicine</i> , 2021, 186, 943-950.	0.4	2
90	Primary care physicians' approaches to low-value prescribing in older adults: a qualitative study. <i>BMC Geriatrics</i> , 2022, 22, 152.	1.1	2

#	ARTICLE	IF	CITATIONS
91	Changes in predicted opioid overdose risk over time in a state Medicaid program: a group-based trajectory modeling analysis. <i>Addiction</i> , 2022, 117, 2254-2263.	1.7	2
92	Characteristics of opioid prescribing to outpatients with chronic liver diseases: A call for action. <i>PLoS ONE</i> , 2021, 16, e0261377.	1.1	2
93	Improving Medication Adherence: Keep Your Eyes on the Prize. <i>Journal of General Internal Medicine</i> , 2017, 32, 236-237.	1.3	1
94	Association between physician adoption of a new oral anti-diabetic medication and Medicare and Medicaid drug spending. <i>BMC Health Services Research</i> , 2019, 19, 703.	0.9	1
95	Reply to Comment on Low-Value Prostate Cancer Screening Among Older Men Within the Veterans Health Administration. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 220-221.	1.3	1
96	Estimating Discounts for Top Spending Drugs in Medicare Part D. <i>Journal of General Internal Medicine</i> , 2020, 36, 2503-2505.	1.3	1
97	Reducing Health Disparities Through Achieving Pharmaco-equity—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 590.	3.8	1
98	Savings from the EpiPen Authorized Generic: a Retrospective Analysis of Medicaid Data. <i>Journal of General Internal Medicine</i> , 2019, 34, 1682-1684.	1.3	0
99	Drug Prices, Rebates, and Discounts—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 399.	3.8	0
100	Disclosure of Article Funding and Conflicts of Interest in High-Impact Clinical Journals. <i>Journal of General Internal Medicine</i> , 2020, 35, 1345-1347.	1.3	0
101	Patterns of clinic switching and continuity of medication for opioid use disorder in a Medicaid-enrolled population. <i>Drug and Alcohol Dependence</i> , 2021, 221, 108633.	1.6	0
102	Primary care physicians' perspectives on Veterans who obtain prescription opioids from multiple healthcare systems. <i>Journal of Opioid Management</i> , 2019, 15, 183-191.	0.2	0
103	Identifying sociodemographic profiles of veterans at risk for high-dose opioid prescribing using classification and regression trees. <i>Journal of Opioid Management</i> , 2020, 16, 409-424.	0.2	0
104	Primary care provider payment models and adherence to anticoagulation in patients with atrial fibrillation. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2021, 27, 1672-1679.	0.5	0
105	Comparison of oral anticoagulation use and adherence among Medicare beneficiaries enrolled in stand-alone prescription drug plans vs Medicare Advantage prescription drug plans. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2022, 28, 266-274.	0.5	0
106	Title is missing!. , 2020, 15, e0235981.		0
107	Title is missing!. , 2020, 15, e0235981.		0
108	Title is missing!. , 2020, 15, e0235981.		0

#	ARTICLE	IF	CITATIONS
109	Title is missing!. , 2020, 15, e0235981.		0